Changing the Paradigm of Cancer Treatment
For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, transforming cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.
To bring about this transformation, we're developing innovative products that harness a patient's own immune system to target and attack cancer cells. In just three years, our singular focus and strategic collaborations, including multiple Cooperative Research and Development Agreements with the National Cancer Institute, have enabled us to advance an industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates to address both hematological (blood-based) and solid cancers.
On October 3, 2017, Kite became a Gilead company with the completion of the acquisition by Gilead Sciences. For further details on the acquisition, click here.